Boston launches Taxus Element in Europe
This article was originally published in Clinica
Boston Scientific has launched its third-generation drug-eluting stent, Taxus Element, in the EU and other countries that recognise the CE mark. Boston CE marked the paclitaxel-eluting device for use in patients including those with diabetes, last month (www.clinica.co.uk, 14 May 2010). The firm CE marked its Promus Element everolimus-eluting stent, which uses the same platinum chromium alloy and strut design as Taxus Element, in October 2009. Boston expects US FDA approval for Taxus Element in mid-2011, and for Promus Element a year later. Japanese approval for Taxus Element is slated for late 2011 or early 2012, and for Promus Element in mid-2012.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.